- Home
- LAB vs ADCT Comparison
LAB vs ADCT Comparison
Compare LAB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- ADCT
- Stock Information
- Founded
- LAB 1999
- ADCT 2011
- Country
- LAB United States
- ADCT Switzerland
- Employees
- LAB N/A
- ADCT N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- LAB Industrials
- ADCT Health Care
- Exchange
- LAB Nasdaq
- ADCT Nasdaq
- Market Cap
- LAB 449.9M
- ADCT 454.5M
- IPO Year
- LAB 2011
- ADCT 2020
- Fundamental
- Price
- LAB $1.23
- ADCT $4.00
- Analyst Decision
- LAB Hold
- ADCT Strong Buy
- Analyst Count
- LAB 2
- ADCT 6
- Target Price
- LAB $1.35
- ADCT $7.60
- AVG Volume (30 Days)
- LAB 1.5M
- ADCT 716.6K
- Earning Date
- LAB 11-04-2025
- ADCT 11-10-2025
- Dividend Yield
- LAB N/A
- ADCT N/A
- EPS Growth
- LAB N/A
- ADCT N/A
- EPS
- LAB N/A
- ADCT N/A
- Revenue
- LAB $169,737,000.00
- ADCT $75,209,000.00
- Revenue This Year
- LAB N/A
- ADCT $11.78
- Revenue Next Year
- LAB N/A
- ADCT $4.83
- P/E Ratio
- LAB N/A
- ADCT N/A
- Revenue Growth
- LAB 79.77
- ADCT 6.35
- 52 Week Low
- LAB $0.92
- ADCT $1.05
- 52 Week High
- LAB $2.25
- ADCT $4.80
- Technical
- Relative Strength Index (RSI)
- LAB 48.04
- ADCT 46.06
- Support Level
- LAB $1.16
- ADCT $3.87
- Resistance Level
- LAB $1.26
- ADCT $4.19
- Average True Range (ATR)
- LAB 0.07
- ADCT 0.30
- MACD
- LAB 0.01
- ADCT -0.05
- Stochastic Oscillator
- LAB 72.50
- ADCT 29.06
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).